Abstract
Purpose
The treatment of giant cell tumor (GCT) of bone remains controversial. Intralesional surgery (curettage) results in a higher rate of local recurrence, but better functional results compared to resection. The aim of this study was to assess whether the use of curettage was successful in the treatment of GCT of long bones. We evaluated the influence of adjuvant treatment, local tumor presentation, and demographic factors on the risk of recurrence.
Methods
We retrospectively reviewed the records of patients treated for GCT of long bones between 1990 and 2013, using curettage. No patient had any treatment other than surgery. After detailed curettage, the bone cavity was filled with bone allografts and/or cement. Recurrence rates, risk factors for recurrence and the development of pulmonary metastases were determined. The minimum follow-up was 24 months.
Results
We enrolled 210 patients with GCT of long bones treated by curettage. The rate of local recurrence was 16.2% (34/210 patients). The median follow-up was 89.2 months. In the multivariate analysis, no significant statistical effect on the local recurrence rate could be identified for gender, patient’s age, Campanacci’s grading, or cement versus bone allografts. The only independent risk factor related to the local recurrence was the site, with a statistically significant higher risk for patients with GCT of the proximal femur.
Conclusions
Our observation on the correlation of tumor location and risk of local recurrence is new. We suggest that patients with GCT of bone in the proximal femur should be followed closely soon after surgery to identify any possible recurrence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lin W-H, Lan T-Y, Chen C-Y et al (2011) Similar local control between phenol- and ethanol-treated giant cell tumors of bone. Clin Orthop 469:3200–3208. doi:10.1007/s11999-011-1962-3
Niu X, Zhang Q, Hao L et al (2012) Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am 94:461–467. doi:10.2106/JBJS.J.01922
Klenke FM, Wenger DE, Inwards CY et al (2011) Giant cell tumor of bone: risk factors for recurrence. Clin Orthop 469:591–599. doi:10.1007/s11999-010-1501-7
Lackman RD, Crawford EA, King JJ, Ogilvie CM (2009) Conservative treatment of Campanacci grade III proximal humerus giant cell tumors. Clin Orthop 467:1355–1359. doi:10.1007/s11999-008-0583-y
Prosser GH, Baloch KG, Tillman RM et al (2005) Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop 435:211–218
Ayerza MA, Piuzzi NS, Aponte-Tinao LA et al (2016) Structural allograft reconstruction of the foot and ankle after tumor resections. Musculoskelet Surg 100:149–156. doi:10.1007/s12306-016-0413-4
Kivioja AH, Blomqvist C, Hietaniemi K et al (2008) Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 79:86–93. doi:10.1080/17453670710014815
Turcotte RE, Wunder JS, Isler MH et al (2002) Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop 397:248–258
Campanacci M, Baldini N, Boriani S, Sudanese A (1987) Giant-cell tumor of bone. J Bone Joint Surg Am 69:106–114
Enneking WF, Dunham W, Gebhardt MC et al (1993) A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop 286:241–246
Sakayama K, Sugawara Y, Kidani T et al (2007) Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg 127:867–872. doi:10.1007/s00402-007-0419-3
Wai EK, Davis AM, Griffin A et al (2001) Pathologic fractures of the proximal femur secondary to benign bone tumors. Clin Orthop 393:279–286
Irwin RB, Sauchak JA, O’Brien MP (1998) Tumors of the proximal femur: case examples and literature review. Orthopedics 21:182–189
Wijsbek AE, Vazquez-Garcia BL, Grimer RJ et al (2014) Giant cell tumour of the proximal femur: Is joint-sparing management ever successful? Bone Joint J 96-B:127–131. doi:10.1302/0301-620X.96B1.31763
Algawahmed H, Turcotte R, Farrokhyar F, Ghert M (2010) High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma. doi:10.1155/2010/586090
Errani C, Ruggieri P, Asenzio MAN et al (2010) Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 36:1–7. doi:10.1016/j.ctrv.2009.09.002
Ghert MA, Rizzo M, Harrelson JM, Scully SP (2002) Giant-cell tumor of the appendicular skeleton. Clin Orthop 400:201–210
O’Donnell RJ, Springfield DS, Motwani HK et al (1994) Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 76:1827–1833
Perrin M, Fraisse J, Cuisenier J (1997) Use of cement for treatment of giant-cell tumors. Eur J Orthop Surg Traumatol 7:95–99
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare to have no conflict of interest.
Rights and permissions
About this article
Cite this article
Errani, C., Tsukamoto, S., Leone, G. et al. Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites. Eur J Orthop Surg Traumatol 27, 813–819 (2017). https://doi.org/10.1007/s00590-017-1983-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00590-017-1983-z